3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
4
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Melanoma
1
Kidney Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
27
Cyclophosphamide
14
Gemcitabine
13
fludarabine
11
Carboplatin
10
aldesleukin
9
Trastuzumab
9
Specimen Handling
9
Nivolumab
9
Magnetic Resonance Spectroscopy
8
Biopsy
8
olaparib
7
Cisplatin
7
Paclitaxel
6
palbociclib
5
atezolizumab
5
Taxes
5
Early Intervention, Educational
5
Oxaliplatin
4
Methods
4
Irinotecan
4
Drug Therapy
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
talazoparib
3
spartalizumab
3
pertuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Genetic Counseling
×
Gynecologic
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled